Navigation Links
Accuray Announces Regionalized Management Strategy for Americas
Date:10/21/2009

SUNNYVALE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today plans to establish an America's region thereby establishing regionalized management and operational oversight worldwide across the entire company.

The formation of this new Americas region, along with the already established regions of Europe, Asia and Japan, gives each region control of revenue and profitability and responsibility for establishing a full range of dedicated services, including sales, marketing and operations, to meet their regional customers' needs. The regions will focus on driving sales and revenue, building market share, and managing the local support functions, while Accuray Corporate will remain focused on global strategy, governance and reporting, and building the necessary platforms to enable efficient and effective operations across the regions.

The newly established Americas region will include the United States, Canada and Latin America. Michael Brandt, who previously served as the General Manager of Accuray Europe, will assume the role of General Manager of the Americas. Jim English, who has been in the Sales organization at Accuray since March 2004, will be promoted to Vice President and will be responsible for all North America sales.

"Creating teams with a regional focus encourages cooperation between functional groups and enables us to be responsive to local market conditions," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "We have seen the benefits of this approach in our international markets and believe it can accelerate our growth in the Americas."

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently more than 176 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to management, operational structure, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2009 fiscal year and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated


'/>"/>
SOURCE Accuray Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
2. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
3. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
4. Flextronics Announces Expansion of Medical Disposables Offering
5. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
6. Speedus Announces Compliance with Nasdaq Marketplace Rules 5250(c)(1) and 4350(b)(1)(B), and Receipt of Noncompliance Notification Related to Nasdaq Marketplace Rule 5550
7. Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM)
8. Sigma-Aldrich Announces SAGE(TM) Priority Partners Program; Seeks Researchers to Evaluate New Knockout Rat Models
9. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
10. Yongye International Announces Completion of Restructuring
11. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  Regulus ... biopharmaceutical company leading the discovery and development of ... drug development candidates at its R&D day, held ... first candidate, RGLS5040, is an anti-miR targeting microRNA-27 ... second candidate, RGLS4326, is an anti-miR targeting microRNA-17 ...
(Date:12/6/2016)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... in the use of cannabinoids for the treatment ... 2015 InMed initiated its COPD program using its ... potential active compounds that can be useful for ... assays using human lung fibroblasts (HFL-1 cell line), ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... "ProBrand Flip ... and all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand ... easy to use drop zones. Editors can select from a variety of flip book ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to present at the International Probiotic Association’s Washington DC workshop on November 2nd. ... to engage in dialog regarding probiotic dietary supplement regulations. , Dr. Leyer ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... because of a higher risk of serious health problems, such as cardiovascular illness, ... Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that ...
Breaking Medicine News(10 mins):